Last updated: February 12, 2026
Market Analysis and Price Projections for NDC 00054-3294
Product Identification
NDC 00054-3294 corresponds to Acalabrutinib (Calquence), developed by AstraZeneca. It’s a selective Bruton’s tyrosine kinase (BTK) inhibitor approved for certain hematologic malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).
Market Size and Growth
The global hematologic malignancies therapeutics market was valued at approximately $12.5 billion in 2022. It is expected to grow at a CAGR of 7-9% through 2030, driven by increased diagnosis rates, expanded indications, and advances in targeted therapies.
Within this market, BTK inhibitors hold a significant share. Ibrutinib, the market leader, generated over $6 billion globally in 2022. Acalabrutinib competes mainly with ibrutinib and zanubrutinib.
Competitive Positioning
- Market Uptake: Approved in 2019, Acalabrutinib's sales have steadily increased, reaching an estimated $1.2 billion in 2022.
- Indications: Approved for MCL, R/R CLL/SLL, and other B-cell malignancies.
- Advantages: Higher selectivity for BTK, fewer off-target effects, and improved tolerability over first-generation BTK inhibitors.
Pricing Strategy and Reimbursement
- Price in the U.S.: The average wholesale price (AWP) is approximately $13,500 per month for standard dosing (calculated at about $162,000 annually).
- Insurance Coverage: Reimbursement policies generally cover this therapy for approved indications, with co-pay assistance programs reducing patient out-of-pocket costs.
- International Pricing: Lower in European and Asian markets due to market dynamics and pricing regulations. For instance, European prices typically range from $80,000 to $120,000 annually.
Revenue Projections
| Year |
Estimated Global Sales |
Key Growth Drivers |
Risks and Challenges |
| 2023 |
$1.5 billion |
Increasing indication approvals, expanding patient populations |
Competition from Zanubrutinib and Ibrutinib, patent expirations (2028 for Calquence) |
| 2024 |
$1.9 billion |
Expansion into new markets, ongoing clinical pipeline |
Pricing pressures, payer consolidation |
| 2025 |
$2.3 billion |
Launch of next-generation formulations, increased adoption |
Competitive landscape shifts, biosimilar encroachment |
Key Market Dynamics
- Patent Expiry: Patents for Calquence are expected to expire around 2028 in major markets, opening opportunities for generics.
- Pipeline: Continued development of combination therapies and expanded indications (e.g., chronic graft-versus-host disease, solid tumors).
- Manufacturing & Supply: AstraZeneca maintains manufacturing investments to meet increasing demand; supply chain stability remains critical.
Regulatory Outlook
- Additional approvals for indications such as Waldenström’s macroglobulinemia and earlier-line treatment are possible through ongoing clinical trials.
- Regulatory incentives may influence pricing and market access strategies.
Price Trends and Future Outlook
- Price Stability: In established markets like the U.S., prices are stable with little fluctuation due to cost control measures and negotiated rebates.
- Post-Patent Market: Prices for biosimilars or generics (post-2028) are expected to decrease by 40-60% over current branded prices, impacting revenue forecasts.
Summary of Key Data Points
- Global Market Value (2022): $12.5 billion (hematologic malignancies)
- Acalabrutinib Sales (2022): Around $1.2 billion
- Average Annual Price (U.S.): ~$162,000 per year
- Patent Expiry: Approximate 2028 in major markets
- Growth CAGR (2023-2030): 7-9%
Key Takeaways
- Acalabrutinib has established a growing presence in the hematologic malignancies market, with sales forecasted to increase through 2025.
- Price projections suggest stability in branded markets until patent expiration around 2028, after which significant price erosion is expected.
- Competitive dynamics include expanding indications, pipeline development, and emerging biosimilar threats.
- Reimbursement policies support ongoing sales, with moderate price stability expected.
FAQs
1. How does Acalabrutinib compare to Ibrutinib?
Acalabrutinib offers increased selectivity for BTK, resulting in fewer off-target effects and potentially better tolerability. Clinical trials indicate comparable or superior efficacy in certain indications, with a better side effect profile.
2. What are the primary drivers for revenue growth?
Expansion into new markets, additional approved indications, and a growing patient base drive sales. Clinical pipeline advancements also support long-term growth prospects.
3. When are generics expected to enter the market?
Patent exclusivity is expected to expire around 2028 in key markets, enabling biosimilar competition which could reduce prices by up to 60%.
4. How do international prices compare to the U.S.?
International prices are significantly lower, averaging between 50-70% of U.S. prices depending on regional pricing regulations and reimbursement systems.
5. What risks could impact future pricing and sales?
Patent expiry, patent challenges, biosimilar entry, competitive drugs (like Zanubrutinib), and payer pricing pressures pose risks to ongoing revenue streams.
Citations
[1] IQVIA, "Global Oncology Market Data," 2022
[2] AstraZeneca, "Calquence Product Label," 2023
[3] EvaluatePharma, "Market Trends in Hematologic Malignancies," 2022
[4] U.S. CMS, "Part B Medicare Rebate Data," 2023
[5] FDA, "Drug Approvals and Indications," 2023
